Center of Oncology, Medical School Split, University Hospital Split, Spinciceva 1, Split, Croatia.
Anticancer Drugs. 2011 Feb;22(2):191-7. doi: 10.1097/CAD.0b013e3283417f3e.
The relative survival of elderly patients with metastatic colorectal cancer (mCRC) is generally worse than that of younger patients because of more advanced stage at presentation, comorbidity and reduced use of optimal therapy. We conducted a prospective phase II trial of the combination of bevacizumab and capecitabine in elderly patients with mCRC. In total 41 patients aged more than or equal to 70 years with mCRC, who had not received chemotherapy earlier for metastatic disease, were enroled. Patients received capecitabine (1000 mg/m twice daily on days 1-14) and bevacizumab (7.5 mg/kg of body weight on day 1). The treatment cycles were repeated every 3 weeks. The overall response rate was 65%, including 13% of patients with a complete response and 53% of patients with a partial response. A further 13% of patients maintained stable disease. The median progression-free survival was 11.5 months and the median overall survival was 21.2 months. Despite the advanced age of participants, the rate of bevacizumab-related and capecitabine-related adverse events was consistent with that reported earlier in the general mCRC population. The combination of bevacizumab and capecitabine is effective and has a favourable tolerability profile and should be considered as an option for the initial treatment of mCRC in elderly patients.
转移性结直肠癌（mCRC）老年患者的相对存活率通常比年轻患者差，因为他们的疾病分期更晚、合并症更多，以及接受最佳治疗的比例更低。我们开展了一项贝伐珠单抗联合卡培他滨治疗老年 mCRC 患者的前瞻性 II 期临床试验。共纳入 41 例年龄≥70 岁、之前未接受转移性疾病化疗的 mCRC 患者。患者接受卡培他滨（1000mg/m2，每日 2 次，第 1-14 天）和贝伐珠单抗（7.5mg/kg，第 1 天）治疗。治疗周期每 3 周重复一次。总缓解率为 65%，包括 13%的完全缓解和 53%的部分缓解。另有 13%的患者疾病稳定。中位无进展生存期为 11.5 个月，中位总生存期为 21.2 个月。尽管参与者年龄较大，但贝伐珠单抗相关和卡培他滨相关不良事件的发生率与之前报道的一般 mCRC 人群一致。贝伐珠单抗联合卡培他滨有效，且耐受性良好，应考虑作为老年 mCRC 患者初始治疗的选择。
